List of Excipients in Branded Drug GEMTESA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sumitomo Pharma America Inc	GEMTESA	vibegron	73336-075	CELLULOSE, MICROCRYSTALLINE	2029-04-02
Sumitomo Pharma America Inc	GEMTESA	vibegron	73336-075	CROSCARMELLOSE SODIUM	2029-04-02
Sumitomo Pharma America Inc	GEMTESA	vibegron	73336-075	FD&C BLUE NO. 2 ALUMINUM LAKE	2029-04-02
Sumitomo Pharma America Inc	GEMTESA	vibegron	73336-075	FERRIC OXIDE YELLOW	2029-04-02

GEMTESA (Vibegron) Excipient Strategy and Commercial Opportunities

Last updated: November 8, 2026

GEMTESA is a once-daily, 75 mg immediate-release film-coated tablet containing vibegron, a beta-3 adrenergic receptor agonist approved for overactive bladder. Its excipient system is conventional, low-cost, and suitable for generic substitution. The principal commercial opportunities are improved swallowing, differentiated dosage forms, combination therapy, manufacturing efficiencies, and lifecycle management around adherence rather than high barriers from the current tablet formulation.

What is the GEMTESA formulation and which excipients does it contain?

GEMTESA is an oral, film-coated tablet. The FDA-approved product contains the following inactive ingredients:

Formulation component	Reported role
Mannitol	Diluent and bulking agent
Croscarmellose sodium	Superdisintegrant
Hydroxypropyl cellulose	Binder
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Titanium dioxide	Opacifier and colorant
Carnauba wax	Polishing or coating aid

The active pharmaceutical ingredient is vibegron, present at 75 mg per tablet. The product is administered once daily, with or without food. The FDA label does not identify a modified-release mechanism, enteric coating, or specialized delivery system. [1]

The formulation has several commercial advantages:

• It uses widely available compendial excipients.
• It avoids complex modified-release technology.
• It supports conventional high-speed tablet manufacturing.
• It has a relatively small tablet burden for chronic use.
• It is compatible with standard immediate-release bioequivalence programs.

The formulation’s simplicity also limits the ability of the originator to create a strong composition-of-matter barrier through excipient selection alone.

What excipient strategy is used in GEMTESA?

The GEMTESA excipient strategy is based on manufacturability and rapid tablet disintegration rather than advanced delivery technology.

Mannitol as the primary diluent

Mannitol provides bulk and contributes favorable mouthfeel compared with some alternative polyols. It is commonly used in oral solid dosage forms where low hygroscopicity and acceptable patient palatability are desired.

For vibegron, mannitol can support:

• Direct compression or a simple granulation process.
• Improved tablet mass control.
• Lower moisture exposure than more hygroscopic fillers.
• A relatively neutral sensory profile.

Potential limitations include cost compared with lactose or some grades of microcrystalline cellulose, compression behavior, and possible gastrointestinal tolerance concerns at higher total excipient loads. The 75 mg drug load is sufficient to reduce, but not eliminate, the importance of excipient volume.

Croscarmellose sodium for rapid disintegration

Croscarmellose sodium absorbs water and expands, helping the immediate-release tablet break apart after administration. This is consistent with a once-daily product that does not depend on prolonged gastrointestinal residence or controlled drug release.

Generic manufacturers can alter the grade, level, or distribution of croscarmellose sodium, but excessive changes may affect:

• Disintegration time.
• Dissolution profile.
• Tablet hardness.
• Friability.
• Sensitivity to compression force.

A formulation that matches the reference product’s dissolution behavior without duplicating the exact excipient percentages may be commercially viable under an abbreviated new drug application, subject to FDA requirements.

Hydroxypropyl cellulose as a binder

Hydroxypropyl cellulose provides granule and tablet cohesion. Its selection indicates a conventional formulation approach with a need to balance mechanical strength against disintegration.

Binder level is a key generic-development variable. Too little binder can produce friable tablets and manufacturing losses. Too much binder can slow disintegration and dissolution. The most commercially useful formulation window is likely one that preserves tablet robustness while avoiding a dissolution penalty.

Magnesium stearate as a lubricant

Magnesium stearate reduces tooling adhesion and improves powder flow during compression. Its concentration, mixing time, and shear exposure require control because over-lubrication can reduce tablet tensile strength or slow wetting and dissolution.

This is a standard manufacturing risk rather than a major patent barrier. Process know-how may still create practical advantages through:

• Optimized lubricant blending time.
• Lower ejection force.
• Improved content uniformity.
• Reduced sticking and picking.
• Better scale-up performance.

Hypromellose, titanium dioxide, and carnauba wax in the coating

The coating system supports appearance, handling, and protection from surface abrasion. It does not appear to provide controlled release. A generic manufacturer may pursue an equivalent film-coating system using different polymer grades, pigments, or polishing materials, subject to product quality and regulatory requirements.

The coating is a potential site for commercial differentiation through:

• Lower coating weight.
• Reduced coating time.
• Improved color consistency.
• Titanium-dioxide-free presentation where permitted.
• Better moisture protection.
• Easier visual identification for older patients.

What commercial opportunities exist for GEMTESA excipients?

The largest opportunities are in formulation optimization and lifecycle management, not in replacing a difficult delivery platform.

1. Smaller or easier-to-swallow tablets

Overactive bladder is prevalent among older adults, a population with increased rates of dysphagia and polypharmacy. A smaller tablet, reduced tablet mass, or improved surface coating could support adherence.

A smaller presentation may require:

• Higher tablet density.
• More efficient excipient selection.
• Granulation optimization.
• Alternative compression tooling.
• A lower-mass coating system.

Any reformulation must preserve dose uniformity, mechanical integrity, dissolution, and bioequivalence.

2. Orally disintegrating or orally dispersible formulations

An orally disintegrating tablet could target patients who have difficulty swallowing conventional tablets. Mannitol is particularly compatible with orally disintegrating dosage forms because of its mouthfeel and cooling sensation.

Potential formulation components include:

• Mannitol-based filler systems.
• Crospovidone or alternative superdisintegrants.
• Taste-masking agents.
• Flavors and sweeteners.
• Low-moisture packaging.
• Direct-compression excipient platforms.

The main technical challenge is taste. Vibegron’s sensory profile would need evaluation before commercialization. An orally disintegrating product would likely require a new formulation, stability program, packaging system, and regulatory submission.

3. Sprinkle, granule, or liquid presentations

A sprinkle formulation could address patients unable to swallow tablets. A liquid suspension could be relevant for long-term-care settings, although chemical stability, dosing accuracy, microbial control, and palatability would add complexity.

Commercial opportunities include:

• Unit-dose oral granules.
• Sachets for dispersion in water.
• Pharmacy-compounded suspension alternatives.
• Administration through feeding tubes, if compatibility is demonstrated.

These products could extend market access without competing solely on tablet price.

4. Pediatric or adolescent development

GEMTESA is approved for adults with overactive bladder. A pediatric formulation would require clinical and regulatory development, and the therapeutic opportunity would depend on pediatric labeling and disease prevalence.

A flexible granule or oral suspension platform would be more suitable than the current film-coated tablet. The excipient strategy would need to address age-specific limits for sweeteners, preservatives, colorants, and polyols.

5. Fixed-dose combination products

Vibegron could be evaluated in combination with agents used for overactive bladder or lower urinary tract symptoms. The most obvious commercial rationale is combination treatment for patients with incomplete response to monotherapy.

Combination development raises technical issues:

• Dose ratio and tablet size.
• Chemical compatibility.
• Dissolution of both active ingredients.
• Separate release requirements.
• Food-effect assessment.
• Stability of the combined product.
• New intellectual property around the combination.

A combination product could protect revenue after loss of exclusivity if it produces clinically meaningful benefits and receives independent FDA approval.

When does GEMTESA lose exclusivity?

GEMTESA was approved by the FDA on December 23, 2020. As a new chemical entity, vibegron was eligible for five years of FDA regulatory exclusivity, subject to the specific regulatory record and any applicable extensions. The base five-year period would run to approximately December 23, 2025. [1,2]

Regulatory exclusivity and patent protection are separate:

Protection	Relevance to GEMTESA
New chemical entity exclusivity	Blocks certain ANDA submissions for five years from approval
Orange Book patents	May delay approval or market entry depending on claim scope and litigation
Pediatric exclusivity	Adds six months only if formally granted
Orphan exclusivity	Not generally associated with GEMTESA’s broad overactive-bladder indication
Formulation patents	Could protect a specific dosage form if listed and enforceable
Method-of-use patents	May cover selected indications or patient populations

The applicable commercial entry date cannot be determined from NCE exclusivity alone. It depends on the current Orange Book patent listings, patent term adjustments, litigation outcomes, and any settlement agreements.

What is the Orange Book status and generic-entry risk for GEMTESA?

GEMTESA is a small-molecule drug, so the relevant generic pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar provisions under section 351(k) do not apply.

Potential generic applicants may pursue:

• Paragraph III certification, accepting later entry.
• Paragraph IV certification, alleging that listed patents are invalid, unenforceable, or not infringed.
• A non-infringement strategy directed at formulation or method-of-use claims.
• A carve-out of patented methods of use under FDA regulations.

The commercial risks are greatest when an ANDA applicant can show that:

1. The reference product is immediate release.
2. The excipient system is conventional.
3. The active ingredient is readily characterized.
4. Bioequivalence can be established with standard pharmacokinetic studies.
5. The proposed product does not require a novel delivery device.

These factors make tablet-based generic competition technically accessible. Excipient patents could still create litigation exposure if they claim a specific composition, dissolution profile, polymorph, or manufacturing process, but broad protection based only on common excipients is generally difficult to sustain.

What patent protection is most relevant to GEMTESA?

The most commercially relevant patent categories are:

• Vibegron compound patents.
• Salt, crystal-form, or polymorph patents.
• Pharmaceutical composition patents.
• Immediate-release tablet patents.
• Method-of-use patents for overactive bladder.
• Combination-treatment patents.
• Manufacturing-process patents.
• Pediatric, liquid, granule, or orally disintegrating formulations.

The current tablet’s conventional excipients are unlikely to create a durable barrier by themselves. The strongest lifecycle opportunities would involve a clinically differentiated dosage form, a new combination, a technically difficult solid form, or a manufacturing process that produces a measurable quality advantage.

Patent diligence should review the current FDA Orange Book, USPTO records, Patent Center filings, and federal court dockets. The relevant questions are whether patents are listed, whether claims cover the approved product, whether the patents remain in force, and whether any Paragraph IV litigation has produced a settlement or stay. [2-4]

Which companies control or commercialize vibegron?

Vibegron originated with Kissei Pharmaceutical. Urovant Sciences obtained rights to develop and commercialize vibegron in the United States. Sumitomo Pharma acquired Urovant and became the U.S. commercial sponsor for GEMTESA. Kissei has retained rights in Japan and certain other territories under the applicable commercial arrangements. [5,6]

The licensing structure creates opportunities for:

• Regional out-licensing.
• Authorized generic arrangements.
• Co-development of new dosage forms.
• Combination-product partnerships.
• Contract manufacturing of tablets or granules.
• Geographic expansion outside the United States.

The business value of an excipient-focused license would depend on whether the license includes formulation patents, manufacturing know-how, regulatory files, and rights to future dosage forms.

How does GEMTESA compare with Myrbetriq from a formulation perspective?

Myrbetriq contains mirabegron and is also an oral beta-3 adrenergic agonist used for overactive bladder. Both products compete in a chronic, once-daily oral market, but their excipient and lifecycle strategies differ.

Attribute	GEMTESA	Myrbetriq
Active ingredient	Vibegron	Mirabegron
Drug class	Beta-3 adrenergic agonist	Beta-3 adrenergic agonist
Primary dosage form	Immediate-release film-coated tablet	Extended-release tablet
Release strategy	Conventional immediate release	Modified release
Generic development	Standard immediate-release bioequivalence pathway	More complex due to extended-release performance
Main excipient opportunity	Swallowability, ODT, granules, combinations	Release-control and formulation replication
Commercial differentiation	Efficacy, safety, adherence, dosage-form lifecycle	Established market presence and extended-release platform

GEMTESA’s immediate-release design lowers manufacturing complexity but may provide fewer formulation barriers than an extended-release product. That makes clinical positioning, physician adoption, contracting, and new dosage forms more important to long-term commercial performance.

What generic launch scenarios exist for GEMTESA?

The practical scenarios are:

1. Delayed ANDA approval: A generic applicant waits for patent or exclusivity resolution.
2. Paragraph IV litigation: The applicant challenges listed patents and seeks approval after litigation or settlement.
3. At-risk launch: A generic launches before final patent resolution, creating injunction and damages exposure.
4. Authorized generic: The sponsor or licensee supplies a lower-priced version before or after independent generic entry.
5. Narrow carve-out: A generic enters with labeling that excludes patented indications or uses.
6. Formulation competition: A rival launches a different dosage form rather than a direct tablet equivalent.

The most disruptive scenario is multiple generic approvals after regulatory exclusivity and patent barriers expire. Price erosion would likely be faster for a conventional immediate-release tablet than for a technically complex modified-release product.

Key Takeaways

• GEMTESA is a 75 mg immediate-release, film-coated vibegron tablet.
• Its excipient system uses conventional mannitol, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, and carnauba wax.
• The current formulation is manufacturable and generic-accessible, but it does not create a major delivery-system barrier.
• The strongest excipient-led opportunities are orally disintegrating tablets, granules, liquids, smaller tablets, and combination products.
• Vibegron’s five-year new chemical entity exclusivity began with FDA approval on December 23, 2020.
• GEMTESA is subject to ANDA, not biosimilar, competition.
• Future value depends on Orange Book patents, formulation claims, method-of-use claims, litigation, settlements, and lifecycle products.
• The most defensible new intellectual property would cover a clinically differentiated dosage form, combination, solid form, or manufacturing process.

FAQs

Can a generic manufacturer use different excipients from GEMTESA?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, but the proposed product must satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, quality, labeling, and inactive-ingredient acceptability.

Is GEMTESA suitable for an orally disintegrating tablet?

Technically, yes. Mannitol and superdisintegrants are compatible with orally disintegrating platforms. Taste masking, moisture control, mechanical strength, and dose uniformity would determine commercial feasibility.

Does GEMTESA have biosimilar competition?

No. Vibegron is a small molecule. Competition would proceed through ANDAs and generic-drug procedures rather than the biosimilar pathway.

Could a new GEMTESA liquid formulation receive separate patent protection?

Yes. A liquid formulation could support patents covering composition, stability, taste masking, dosing, packaging, or manufacturing. Patent strength would depend on novelty, non-obviousness, claim scope, and demonstrated technical performance.

Is GEMTESA easier to copy than Myrbetriq?

From a formulation perspective, GEMTESA’s immediate-release tablet is generally less complex to reproduce than Myrbetriq’s extended-release product. The actual entry date still depends on regulatory exclusivity, Orange Book patents, litigation, and settlement terms.

References

1. U.S. Food and Drug Administration. (2020). GEMTESA (vibegron) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Patent and Trademark Office. (2024). Patent Center.
4. U.S. Courts. (2024). PACER federal court records.
5. Sumitomo Pharma Co., Ltd. (2024). Annual report and corporate disclosures.
6. Kissei Pharmaceutical Co., Ltd. (2024). Corporate and product licensing disclosures.